Results 1 to 10 of about 94,027 (167)
Comparison of early versus late addition of granulocyte and monocyte adsorption for incomplete remission induction in ulcerative colitis [PDF]
JGH OpenBackground and aim Ulcerative colitis (UC) is characterized by repeated relapse and remission. Because no fundamental therapeutic strategy has been established, the treatment goal is generally to maintain the remission phase for a long period after rapid
Keiichi Tominaga +14 more
doaj +2 more sources
Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy
Annals of Medicine, 2022 Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare clinical syndrome with a high mortality rate. There is no biomarker to predict the early therapeutic response.
Zhengjie Hua +5 more
doaj +1 more source
Methotrexate for induction of remission in ulcerative colitis [PDF]
Cochrane Database of Systematic Reviews, 2014 Ulcerative colitis (UC) is a chronic inflammatory bowel disease. Corticosteroids and 5-aminosalicylates are the most commonly used therapies. However, many patients require immunosuppressive therapy for steroid-refractory and steroid-dependent disease.
Nilesh, Chande +3 more
openaire +2 more sources
Journal of Nepal Medical Association, 2021 Introduction: Treatment of lupus nephritis consists of six months of induction immunosuppression followed by years of maintenance immunosuppression.
Shailendra Shrestha, Rahul Yadav
doaj +1 more source
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study [PDF]
Intestinal Research, 2021 Background/Aims The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718).
Choon Jin Ooi +7 more
doaj +1 more source
Remission induction in acute myeloid leukemia [PDF]
International Journal of Hematology, 2012 Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 + 3) has become the standard of ...
Eytan M, Stein, Martin S, Tallman
openaire +2 more sources
EClinicalMedicine, 2020 Background: The therapeutic role of methotrexate (MTX) for management of inflammatory bowel disease (IBD) remains unclear. Methods: We systematically reviewed randomized, controlled trials (RCTs) of MTX for induction and maintenance of remission in IBD ...
Ole Haagen Nielsen +3 more
doaj +1 more source
A case of regression of atypical dense deposit disease without C3 deposition in a child [PDF]
Korean Journal of Pediatrics, 2010 Dense deposit disease (DDD) is a rare disorder characterized by the deposition of abnormal electron-dense material within the glomerular basement membrane of the kidneys. The diagnosis is made in most patients between 5 and 15 years of age, and within 10
Min Sun Kim +3 more
doaj +1 more source
Natalizumab for induction of remission in Crohn's disease [PDF]
Cochrane Database of Systematic Reviews, 2018 This systematic review update summarizes the current evidence on the use of natalizumab for induction of remission in Crohn's disease (CD).To determine the efficacy and safety of natalizumab for induction of remission in CD.We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Trials Register, and clinicaltrials.gov from inception to
Seana Ml, Nelson +3 more
openaire +2 more sources
Probiotics for induction of remission in Crohn's disease
Cochrane Database of Systematic Reviews, 2020 Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract, in which the pathogenesis is believed to be partly influenced by the gut microbiome. Probiotics can be used to manipulate the microbiome and have therefore been considered as a potential therapy for CD.
Limketkai, Berkeley N +3 more
openaire +3 more sources